Articles

Updated phase 2 study results of lerociclib (G1T38) combined with fulvestrant support continuous dosing without a drug holiday. Read More ›

In the MONARCH plus study, the majority of abemaciclib-associated diarrhea events were low grade in severity and well managed by antidiarrheal medications, dose omissions, and/or dose reductions. Read More ›

In a range of groups with PIK3CA alterations, recent findings demonstrate a clear and consistent clinical benefit of alpelisib when combined with fulvestrant, which was detected in circulating tumor DNA by next-generation sequencing. Read More ›

Updated overall survival results from the phase 3 MONALEESA-7 trial show that in a 4-year extended follow-up study of pre- and perimenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, ribociclib plus endocrine therapy exhibited a clinically relevant overall survival benefit. Read More ›

BYLieve study results show that alpelisib combined with fulvestrant demonstrates clinically meaningful efficacy and manageable toxicity in patients with hormone receptor–positive, HER2-negative, PIK3CA mutation–positive advanced breast cancer. Read More ›

Analysis from the PALOMA-3 clinical trial showed that the combination of palbociclib and fulvestrant improved overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer. Read More ›

While radiation therapy is not currently used in combination with CDK4/6 inhibitors in clinical trial protocols, findings from this study support future consideration of this approach in clinical studies. Read More ›

In this broad study of a diverse population, adverse events associated with the combination of ribociclib plus letrozole were manageable and consistent with previous phase 3 trials of the same combination, and adverse events of special interest markedly decreased over time. Read More ›

While showing comparable efficacy, the 3 approved CDK4/6 inhibitors differ in safety and tolerability profiles. Read More ›

Adopting a maintenance program of everolimus combined with aromatase inhibitors, outcomes were not improved in patients with metastatic breast cancer who were deemed possible candidates for first-line chemotherapy. Read More ›